In the past week, ITOS stock has gone up by 22.66%, with a monthly gain of 43.72% and a quarterly surge of 13.09%. The volatility ratio for the week is 7.17%, and the volatility levels for the last 30 days are 7.66% for ITeos Therapeutics Inc The simple moving average for the past 20 days is 16.18% for ITOS’s stock, with a -13.45% simple moving average for the past 200 days.
Is It Worth Investing in ITeos Therapeutics Inc (NASDAQ: ITOS) Right Now?
The stock has a 36-month beta value of 1.36. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ITOS is 33.10M, and at present, short sellers hold a 7.65% of that float. On May 13, 2025, the average trading volume of ITOS was 426.49K shares.
ITOS) stock’s latest price update
The stock price of ITeos Therapeutics Inc (NASDAQ: ITOS) has jumped by 17.34 compared to previous close of 6.92. Despite this, the company has seen a gain of 22.66% in its stock price over the last five trading days. globenewswire.com reported 2025-05-13 that – GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival
Analysts’ Opinion of ITOS
Many brokerage firms have already submitted their reports for ITOS stocks, with Wells Fargo repeating the rating for ITOS by listing it as a “Overweight.” The predicted price for ITOS in the upcoming period, according to Wells Fargo is $31 based on the research report published on August 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ITOS reach a price target of $37. The rating they have provided for ITOS stocks is “Buy” according to the report published on May 05th, 2021.
Robert W. Baird gave a rating of “Outperform” to ITOS, setting the target price at $45 in the report published on October 08th of the previous year.
ITOS Trading at 22.04% from the 50-Day Moving Average
After a stumble in the market that brought ITOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.58% of loss for the given period.
Volatility was left at 7.66%, however, over the last 30 days, the volatility rate increased by 7.17%, as shares surge +46.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +15.88% upper at present.
During the last 5 trading sessions, ITOS rose by +22.36%, which changed the moving average for the period of 200-days by -51.53% in comparison to the 20-day moving average, which settled at $6.99. In addition, ITeos Therapeutics Inc saw 5.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITOS starting from Gall Matthew, who purchase 5,000 shares at the price of $7.73 back on Nov 19 ’24. After this action, Gall Matthew now owns 65,429 shares of ITeos Therapeutics Inc, valued at $38,635 using the latest closing price.
Stock Fundamentals for ITOS
Current profitability levels for the company are sitting at:
- -4.35 for the present operating margin
- 0.99 for the gross margin
The net margin for ITeos Therapeutics Inc stands at -3.74. The total capital return value is set at -0.25. Equity return is now at value -23.68, with -20.30 for asset returns.
Based on ITeos Therapeutics Inc (ITOS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.7.
Currently, EBITDA for the company is -159.53 million with net debt to EBITDA at 1.02. When we switch over and look at the enterprise to sales, we see a ratio of 4.53. The receivables turnover for the company is 10.7for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.13.
Conclusion
To sum up, ITeos Therapeutics Inc (ITOS) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
